Pharmacokinetic/Pharmacodynamic of ceftolozane/tazobactam in critically ill patients receiving extracorporeal membrane oxygenation (ECMO): a retrospective cohort analysis.

Crit Care · 2025 · PMC12400648 · PMID 40887639

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with severe renal impairment (CrCl ≤ 30 mL/min) or moderate impairment (CrCl 30–80 mL/min) showed a trend toward increased odds of target attainment (OR 9.87, 95% CI 1.00–1331.19), but this was not statistically significant ( p = 0.050).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.